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Discontinuation of denosumab results in a marked increase in bone turnover markers 
(BTM) above baseline, known as “rebound phenomenon”. This is accompanied by a 
decrease in bone mineral density (BMD) and an increase in the risk of vertebral 
fractures, particularly multiple vertebral fractures. It has been suggested that the 
administration of antiresorptive drugs could prevent the turnover rebound. Therefore, 
we have considered important to verify that the administration of antiresorptives after 
denosumab discontinuation certainly prevents the rebound of BTM.  
We report here a case series of thirteen patients with osteoporosis who had received 
denosumab for more than four years. Approximately 6 months after the last denosumab 
injection, they were given a single infusion of zoledronate (5 mg), drug chosen due to its 
potency and posology. They were followed-up for over a two-year period, in which none 
of them presented any clinical fractures. Furthermore, no single value of CTX nor lumbar 
spine BMD surpassed their corresponding baseline at any time. 
So, as a result of our study we can confirm that an injection of zoledronate at denosumab 
discontinuation seems to adequately prevent the rebound phenomenon. 




Tras suspender el tratamiento con denosumab se produce un aumento de los 
marcadores bioquímicos de remodelado óseo por encima de los valores de partida, 
conocido como “efecto rebote”. Este se acompaña de una disminución de la densidad 
mineral ósea (DMO) y un aumento del riesgo de fracturas vertebrales, especialmente 
fracturas vertebrales múltiples. Se ha sugerido que la administración de fármacos 
antirresortivos podría prevenir este efecto rebote. Por tanto, hemos considerado 
importante verificar que la administración de antirresortivos tras la suspensión de 
denosumab previene realmente el incremento de los marcadores de remodelado óseo. 
Describimos los casos de trece pacientes con osteoporosis que habían recibido 
denosumab durante más de cuatro años. Aproximadamente 6 meses después de la 
última inyección de denosumab recibieron una infusión intravenosa de 5 mg de ácido 
zoledrónico, fármaco escogido por su elevada potencia y su posología. Fueron seguidos 
durante un periodo de dos años, en el que ninguno presentó fracturas clínicas. Además, 
ningún valor de CTX ni la DMO en la columna lumbar sobrepasó su nivel basal 
correspondiente en ningún momento. 
Por tanto, como resultado de nuestro estudio, podemos decir que una infusión de 
zoledronato tras la suspensión de denosumab parece prevenir adecuadamente el 
fenómeno rebote.     
Palabras clave: osteoporosis, denosumab, zoledronato, fracturas clínicas, efecto rebote.  
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2. INTRODUCTION 
2.1.  Bone structure 
Based on the macroscopic and microscopic structure, we can distinguish cortical and 
trabecular bone. Cortical bone constitutes the outer part of all skeletal structures and it 
is dense and compact. This type comprises 80% of the skeleton, but, due to its 
composition, it only represents 30% of the bone surface. On the other hand, trabecular 
bone is less dense, more elastic, and has a higher turnover rate. It is found inside the 
bodies of the vertebrae, in the inner portions of the pelvis and in the large bones’ 
epiphysis (1).  
In cortical bone, the lamellae are arranged in concentric cylinders which have a blood 
vessel as their center, constituting Havers systems. In trabecular bone, the lamellae are 
arranged parallel to each other in bundles, equivalent to open Havers systems. Both 
lamellar systems are known as osteons, the basic structural units. 
Bone is a specialized type of connective tissue consisting of a mineralized matrix and 
three types of cells: osteoblasts (OB), osteocytes and osteoclasts (OC). These cells are 
the responsible for the dynamic processes that take place in bones. 
- Osteoblasts (OB) are differentiated products of mesenchymal stem cells, sharing their 
origin with adipocytes, fibroblasts and myocytes. They can be at rest, flattened on the 
surface as lining osteoblasts, or producing the bone matrix constituents.  
- Osteocytes come from osteoblasts embedded in the matrix that has been produced by 
themselves. These cells are able to detect both mechanical loading and microinjuries 
and, in response, they enhance remodeling activity by recruiting osteoclasts. 
- Osteoclasts (OC) are giant multinucleated cells that derive from hematopoietic cells of 
the mononuclear lineage. Their function is to resorb bone, action mediated through 
hydrogenions and proteolytic enzymes, such as cathepsin K.  
Bone matrix has organic and inorganic components. The former mostly consists of type 
I collagen fibers (95%) and non-collagenous proteins. The inorganic components are 
mainly made up of calcium phosphate, deposited as hydroxyapatite crystals or in an 
amorphous form in 99% of the organic matrix. The remaining 1% has no mineral salt 
deposits and is called osteoid. 
2.2. Bone physiology 
The continuous transformations undergone by the bone can be systematized in two 
types: 
- Modeling: the set of modifications to maintain the morphological characteristics and 
adapt to mechanical loads. It occurs during growth and fracture repair resulting in bone 
mass accrual. In this process, the formation and resorption occur independently at 
different spots.  
- Remodeling: the process that continuously renews the bone to prevent the 
accumulation of fatigue injuries and to adapt to the mechanical needs. It is carried out 
by the successive action of osteoclasts and osteoblasts at a particular point on the bone 
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surface (coupling). The newly formed bone is deposited in layers, initially without 
mineralization (osteoid).  
Figure 1. Bone remodeling (2) 
 
Remodeling is a finely balanced, coupled and sequential process (indicated by the 
dashed arrows). Osteoclasts resorb bone releasing growth factors and calcium. RANKL, 
presented by osteoblastic cells and M-CSF are critical for their maturation. Osteoblasts 
replace the voids with new bone, a process that is dependent on osteoblast 
commitment, proliferation and differentiation paired with osteoblast production of type 
I collagen and its subsequent mineralization to form the calcified matrix of bone. 
Osteocytes, sense mechanical strain, signal to osteoclasts and osteoblasts, participating 
in the remodeling process (3). Bone lining cells have been proposed to form both a 
canopy over remodeling sites and a layer over bone surfaces, as well as a conduit to 
communicate with osteocytes (4). The endosteum and periosteum contain a population 
of tissue macrophages, termed osteomacs (5).  
M-CSF, macrophage colony stimulating factor; RANK, receptor activator of NF-κB; 
RANKL, RANK ligand. 
2.3. Regulation of bone remodeling and bone turnover 
A large number of factors, both local and general, are involved in the regulation of bone 
remodeling.  
- Local regulation:  
Osteocytes detect when a bone multicellular unit needs to be renewed and they send 
various signals to the surface. Some of them, like vascular endothelial growth factor 
(VEGF), attract capillaries and, with them, OC precursors. Others, receptor activator of 
NF-κB ligand (RANKL) and proinflammatory cytokines (IL-1, TNF, IL-6), stimulate these 
precursors to mature and carry out their function. Once the appropriate amount of bone 
is destroyed OCs are inhibited by osteoprotegerin (OPG), which binds to RANKL, and 
TGF-β. 
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The moment bone resorption is completed, the formation of new bone begins, with the 
OBs being stimulated by substances. These substances are released from the bone 
during its resorption (TFG-β) or produced by the OBs (Wnt proteins and bone 
morphogenetic proteins). The main inhibitory signal to terminate osteoblastic activity is 
the sclerostin. Sclerostin is produced by osteocytes and inhibits the action of Wnt 
proteins.  
- Systemic regulation: 
First of all, the calciotropic hormones have an important role in the bone metabolism. 
Calcitonin inhibits directly the osteoclasts. The parathyroid hormone and calcitriol 
increase the RANKL/OPG ratio, stimulating osteoclast activity. Nevertheless, the latter 
results in a positive balance because it enhances intestinal calcium and phosphorus 
absorption and diminish PTH secretion.  
Estrogens affect inhibiting OC directly and indirectly through OB. Furthermore, they 
upregulate RANKL and cytokines production by T cells.   
Glucocorticoids restrain bone formation, but they also can, temporarily, rise 
RANKL/OPG fraction, indirectly stimulating OC.  
Bone modeling regulators are less well known. The main stimulating factor is mechanical 
overload, and the hormones accomplishing the same goal in the periosteum are 
testosterone, GH, IGF-1, Wnt proteins and PTH. Estrogens, on the contrary, have been 
described as inhibitors. 
2.4. Osteoporosis 
Osteoporosis is characterized by an increase in skeletal fragility with a tendency to 
develop fractures, due to a decrease in bone mass and an alteration in bone quality. The 
decrease in bone mass is established in the trabecular bone by thinning or 
disappearance of the trabeculae, and in the cortical bone by its thinning and increase in 
porosity. The quality alteration covers two aspects: the modifications in the bone tissue 
itself and structural alterations such as a decrease in the connection between 
trabeculae. These events are asymptomatic until a fracture occurs. 
2.4.1. Risk factors and epidemiology 
Osteoporosis is a multifactorial disease in which age, along with being a female, are the 
main risk factors. The reason why women are at a higher risk of suffering from it is 
explained by the acquisition of less bone mass during development and the estrogen 
depletion after menopause. The percentage of postmenopausal women who, regardless 
of having suffered fractures, have bone density values in the osteoporotic range varies 
from 15% to 30%, depending on whether the measurement is taken at a single site or at 
several sites. 
The turnover increase in the postmenopause is considered to affect fundamentally the 
trabecular bone (predisposing principally to vertebral fracture), while aging itself would 
also affect the cortical bone, being more common the hip fracture.  
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Other important risk factors are personal or family history of osteoporotic fracture and 
a low body mass index (BMI) (≤ 19 kg/m2). A sedentary lifestyle, smoking and an 
excessive alcoholic intake also contribute negatively. 
Regarding secondary osteoporosis we can find hyperthyroidism, hyperparathyroidism, 
hypercortisolism, hypogonadism, myeloma, glucocorticoids, rheumatoid arthritis and 
other conditions as triggering factors. 
2.4.2. Bone turnover markers (BTMs) 
BTMs provide a dynamic assessment of skeletal activity and high levels can predict rapid 
rates of bone loss and an increased fracture risk independent of BMD (6–8). Clinical trials 
have shown that early changes in BTMs are associated with long-term BMD changes in 
women taking antiresorptive (9) or anabolic (10) drugs. Moreover, they respond quickly 
to therapeutic intervention (11).  
- Serum C-terminal telopeptide type-1 collagen (CTX): is the preferred resorption 
marker. 
- Serum carboxyterminal propeptide of type-I collagen (PINP): is the favorite to 
represent bone formation. 
- Alkaline phosphatase: is also a formation marker but due to its low sensitivity is only 
useful in conditions with an intense turnover rate, like Paget disease. 
2.4.3. Treatment 
Preventive measures 
The first step to reduce fracture risk involves fall reduction strategies like establishing 
muscle and balance training, correcting impaired vision or hearing, diminishing fall risk 
inducing drugs, smoking cessation and limiting alcohol intake (12). 
Moreover, an adequate protein, calcium (1000-1200 mg/day) and vitamin D (800-1000 
UI/d) intake through diet, preferred, or supplements, is necessary. 
Pharmacological agents 
US guidelines recommend pharmacologic therapy for postmenopausal women with 
(11): 
- A bone density T-score < -2.5 standard deviation (SD) in the lumbar spine, femoral neck, 
total hip, or distal radius. 
- A -1.0 SD < T-score < -2.5 SD who have:  
- Suffered a fragility fracture of the hip or spine. 
- A FRAX 10-year probability of ≥3% for hip fracture or ≥20% for major 
osteoporotic fracture 
We can classify osteoporosis drugs by their mechanism of action (13,14): 
 Inhibition of bone resorption 
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- Bisphosphonates carry out their effect by binding to active sites of bone remodeling 
and inhibiting OC.  
Alendronate (oral), risedronate (oral) and zoledronic acid / zoledronate (injectable) have 
demonstrated to reduce the risk of vertebral, hip and other nonvertebral fractures, 
while ibandronate (oral) has only been shown to reduce the risk of vertebral fractures. 
Adverse effects most commonly seen with oral bisphosphonates are gastrointestinal, 
like esophagitis and diarrhea, whereas with IV bisphosphonates acute-phase reactions 
consisting of low-grade fevers, arthralgias and myalgias have been reported. 
Infrequently, some patients have experienced ocular inflammation. This pharmacologic 
class is contraindicated in patients with renal impairment (creatinine clearance <35 
mL/min).  
More serious adverse effects include osteonecrosis of the jaw (ONJ) and atypical femoral 
fractures (AFFs). ONJ incidence is higher in patients with comorbidity (cancer or 
immunosuppression) treated with high-dose IV bisphosphonates. Moreover, dental 
extractions, periodontal infection and denosumab use increase the risk of ONJ. AFFs 
(3.2-50 cases / 100,000 person-years) occurs more frequently with long-term treatment, 
raising its incidence to 100 cases per 100,000 person-years. 
- Denosumab is a fully human monoclonal antibody (IgG2) with high affinity and 
specificity for the RANKL. It mimics the action of endogenous osteoprotegerin. This 
binding prevents the RANKL action on the RANK receptor of OCs which results in a 
reduction in the number and activity of these cells, and ultimately in a decrease in bone 
resorption (15). 
It is effective against both types of fractures too, being an alternative in patients who 
have not responded to or cannot tolerate bisphosphonates. A 60 mg dose is injected 
every 6 months subcutaneously. 
Its pharmacokinetics is not linear, and three phases have been observed. One of 
prolonged absorption at 5 to 21 days after its administration. A prolonged half-life of up 
to 32 days and a rapid terminal phase when the concentration is less than 1,000 ng/ml 
(16). It has been estimated that the time it takes to reach the maximum concentration 
of the drug in the body is 26 days. 
Like bisphosphonates, denosumab can lead to the development of ONJ and AFFs, which 
explains the drug holidays’ existence. Its main limitation though, consists in the rebound 
effect produced after its discontinuation, the cornerstone of this article. However, it can 




Figure 2. Multiple vertebral fractures in 
a patient 7,5 months after the last 
denosumab injection (17). 
Indicated by the yellow arrows the 
fractures located in T11, T12, L2-L5.  
- Selective estrogen receptor modulators (SERM) were synthesized to act like estrogens 
but avoiding their adverse effects, principally cardiovascular disease. There are two 
SERMs available, raloxifene and bazedoxifene, both useful specifically for vertebral 
fracture prevention. Also, raloxifene has been shown to reduce the risk of invasive 
breast cancer.  
Women under this treatment can suffer hot flashes, leg cramps and peripheral edema. 
In addition, like estrogens, they increase the risk for venous thromboembolic events. 
- Calcitonin has been removed from the market due to the limited evidence of its efficacy 
and the doubts about its safety. 
 Stimulating bone formation  
- PTH analogs increase BMD by stimulating bone formation when administered 
intermittently, once-daily. Approved drugs include teriparatide, the recombinant 1-34 
sequence of human PTH, and abaloparatide, a synthetic analog of human PTHrP. They 
are not first-line therapy, but they can be used in postmenopausal women at high 
fracture risk not tolerating or responding to other treatments. In contrast, it is 
contraindicated in patients with preexisting hypercalcemia, history of bone 
radiotherapy, bone metastases, or skeletal malignancies. The treatment with these 
drugs must be discontinued after 2 years but should be followed up by other 
antiresorptive medication.  
Adverse effects include injection-site reactions, nausea, arthralgia (teriparatide), 
hypotension and tachycardia. Transient hypercalcemia and hypercalciuria can occur. 
 Inhibition of bone resorption and stimulation of bone formation 
- Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin.  
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Arthralgia and headache are the most common adverse effects reported. More worrying 
are the cardiovascular events, who has led to its prohibition in patients who had suffered 
a myocardial infarction within the previous year. 
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3. HYPOTHESIS AND OBJECTIVES 
Ten-years of therapy with denosumab results in continuous bone mineral density (BMD) 
gains at the lumbar spine and hip, without reaching a plateau. This leads to a decrease 
in the incidence of fractures, with a good safety profile (18). But, to prevent ONJ and 
AFFs, denosumab cannot be taken life-long. Another reason to discontinue denosumab 
treatment, is an insufficient or even an ineffective response, reflected in BMD, to this 
treatment. 
Unlike bisphosphonates, denosumab does not attach to bone, and therefore its effect 
on bone resorption ceases when withdrawn. Two studies (19,20) carried out about 10 
years ago showed that the discontinuation of denosumab is followed by a marked 
increase in bone turnover markers (BTM), which rise well above the baseline values 
(about 60% above baseline level and 120-140% above post-denosumab treatment 
levels). This increase was described as a “rebound phenomenon”. This effect is believed 
to occur in view of a compensatory upregulation of the RANK receptors on osteoclast 
precursors while in presence of denosumab. It peaks during the year following cessation 
of denosumab activity and lasts for approximately two years. BMD decreases at the 
spine and hip during the first year, so that the increase achieved during denosumab 
treatment is lost.  
More recently, several case reports have pointed out that, in some patients, the 
discontinuation of denosumab is associated with the development of vertebral 
fractures, and more specifically of multiple vertebral fractures (21–24). A radiography 
showing these multiple vertebral fractures can be seen in Figure 2. These fractures occur 
mainly over a period of one or two years after discontinuation of denosumab, 
corresponding with the rebound phenomenon. In fact, both the loss in the BMD gained 
with denosumab treatment and the increase in vertebral fractures are considered to be 
due to the rebound phenomenon shown by the increase in BTM.   
Therefore, it should be expected that, if the rebound phenomenon is prevented, the 
decrease in BMD and the rise in bone fractures could be avoided or at least reduced. 
That is the reasoning behind the experts' recommendation regarding administering an 
antiresorptive upon cessation of denosumab treatment. The ECTS, for instance, has 
stated that “bisphosphonate therapy should be considered to reduce or prevent the 
rebound increase in bone turnover” (25). Due to its greater potency and its easy 
posology (a single injection), zoledronate could be the drug of choice for it. 
In accordance with the above, it must be concluded that it is important to verify that the 
administration of antiresorptives (e.g., zoledronate) after denosumab discontinuation 
certainly prevents the rebound of BTM. Along with it, we must take note of the changes 
in the BMD and in the incidence of fractures, although the latter will certainly be more 
difficult to assess because it requires larger samples. To date, there are very few studies 
that have analyzed these issues. In the article by Anastasilakis et al (26), zoledronate 
infusion in 27 women previously treated with denosumab was followed by significant 
but small increases in serum P1NP and CTX during the first year and stabilization 
thereafter. However, in 30 women who did not received zoledronate after denosumab 
treatment, BTM increased markedly at 15 months. BMD decreased in both groups of 
patients two years after denosumab discontinuation, but the decrease was much 
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smaller in the zoledronate group. More recently, Everts-Graber et al (27) have shown a 
similar pattern in BMD changes, but their assessment of BTM is limited and insufficient 
to enable us to reach a clear conclusion about the zoledronate impact on the rebound 
phenomenon. Although P1NP and CTX are reported on some 20 patients who received 
one infusion of zoledronate after stopping denosumab, their baseline levels are not 
given. Furthermore, neither the time at which the zoledronate was administered, nor 
the time elapsed between its administration and the measurement of the BTM are 
specified. 
The randomized clinical trial still ongoing by Sølling et al. (28) studies BMD (at the lumbar 
spine, total hip and femoral neck), CTX and the onset of clinical fractures in 61 patients 
after denosumab discontinuation. They were randomly allocated to three groups, in 
each of which patients received the zoledronate infusion at three different intervals 
after the last denosumab injection. In one group zoledronate infusion was given 6 
months after denosumab discontinuation, in another 9 months after discontinuation 
and the observation group, who received the zoledronate infusion when bone turnover 
had increased, with the cutoff value being CTX > 1,26 μg/L (50% above the normal range 
for postmenopausal women and elderly men), no injection was given later than 12 
months after discontinuation. The results from the first 12 months after the initial 
administration of zoledronate suggest that in patients discontinuing denosumab after 
long-term treatment a single intravenous infusion of zoledronate 5 mg is not sufficient 
to completely prevent bone loss. Based on the rapid increase in CTX in the 6-month 
group this seems the most appropriate option and proposes the possible benefit of 
another zoledronate infusion 3 to 6 months later. Also, the outcomes evoke that the 
treatment duration with denosumab and the baseline CTX levels are important 
determinants for the zoledronate efficacy to maintain the suppression of bone turnover. 
These are the reasons why we consider it appropriate to add some information on this 
issue. In the present article we report on the issue of BTM and BMD changes in patients 
who had been on denosumab for at least two years and were transitioned to 
zoledronate at the time of denosumab discontinuation. 
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4. PATIENTS AND METHODS 
4.1. Patients 
We report here thirteen patients (twelve women, one men) treated in the Bone 
Metabolism Unit of a tertiary-care center (Hospital Universitario Marqués de Valdecilla) 
in Northern Spain, who received zoledronate after discontinuing denosumab, and were 
followed-up for a mean of 20 months. Their mean age was 70±8 years (range, 55-83 
years).  
Five patients had previous fragility fractures: vertebral (n=3), hip (n=1) and proximal 
humerus fracture (n=1). Seven patients had previously received bisphosphonates and 
were shifted to denosumab because the densitometric response was considered 
insufficient. 















1 72 F 31 Yes No 65 26 21 
2 71 F 29 No No 30 22 21 
3 65 F 27 Yes No 60 25 15 
4 66 F 30 No No 66 25 15 
5 66 F 24 No Yes 56 25 15 
6 70 F 23 No Yes 60 24 15 
7 76 F 25 No Yes 66 24 21 
8 83 F 28 Yes Yes 48 26 20 
9 81 F 32 No Yes 42 26 22 
10 55 M 31 Yes Yes 36 24 22 
11 60 F 18 No No 72 26 23 
12 76 F 30 No No 54 29 12 
13 68 F 27 Yes Yes 30 32 34 
F: female; M: male; BMI: body mass index; Fx: fracture; BP: bisphosphonates; Dmab: 
denosumab; Zol: zoledronate. Months Dmab: months of treatment with dmab; Weeks 
Dmab-Zol: weeks since a new denosumab injection should be given and the 
administration of zoledronate; Months post-Zol: months of follow-up after 
administration of zoledronate. 
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No patient was taking any drug related to the development of osteoporosis or fragility 
fractures. Denosumab discontinuation was decided by the attending clinician because 
the T-score was above -2.5 and there was no recent history of fracture. The number of 
denosumab injections ranged between 4 and 12, with a mean of 8. The duration of 
denosumab treatment ranged from 30 months to 72 months. 
Zoledronate infusion was given an average of 6.3±0.8 months after the last denosumab 
injection. All patients received vitamin D supplements to maintain serum 25OHD levels 
between 20 and 40 ng /mL. A calcium-rich diet was advised, and oral supplements were 
prescribed (500 mg/d) only when dietary calcium intake was insufficient. 
After zoledronate injection, patients were clinically followed for 20±5 months (range 15-
34) and questioned specifically regarding the development of clinical fractures. Serum 
P1NP and CTX levels were determined with automatized chemiluminescence assays 
(IDS-iSYS Multi-Discipline Automated Analyzer; Tyne and Wear, UK) in the morning after 
overnight fasting. Sensitivity was 1 ng/ml and 0.033 ng/ml, respectively. Normal 
premenopausal ranges were 19-76 ng/ml for P1NP and 0.034-0.635 ng/ml for CTX. For 
postmenopausal women, normal ranges were 21-102 ng/ml and 0.034-1.037 ng/ml 
respectively. Intra- and inter-assay coefficients of variation were 6% and 8% for P1NP 
and 7% and 6% for CTX. We considered as least significant change (LSC) a difference of 
25% for both markers, as proposed by the International Osteoporosis Foundation (29). 
BTM were measured before starting the denosumab treatment (T0 or baseline), at the 
time of transition from denosumab to zoledronate (T1), 6 months (approximately) after 
zoledronate injection (T2), and at the end of the follow-up period (T3). BMD was 
measured at the lumbar spine, femoral neck, and total hip by dual-energy X-ray 
absorptiometry (DXA) using an Hologic device (Hologic QDR 4500, Bedford, MA, USA). 
In-vivo precision was 0.4%-1.5% at the different measurement sites. Results were 
expressed as gr/cm2 and T-score. We considered as LSC a change ≥ 5% at the spine and 
≥4% at the FN, as proposed by the International Foundation for Osteoporosis (29). BMD 
was measured at T0, T1 and T3. 
4.2. Statistical analysis 
Quantitative variables are expressed as mean ± SD, and qualitative variables as numbers 
and percentages. Wilcoxon signed rank test was used to compare BTM and BMD values 




5. RESULTS  
5.1. Serum P1NP levels 
Serum P1NP levels (Figure 3) were 47.6±31.1 ng/mL at baseline (T0). At T1, after 
denosumab treatment, they had fallen to 12.6±5.5 ng/mL (p=0.002), which means a 
decrease of 74%. About six months after zoledronate administration (T2), P1NP levels 
had increased to 21.9±7.5 ng/mL (p=0.011 vs. T1), which still means a 54% decrease 
from baseline (p=0.015). Individual values ranged from 10 to 33 ng/mL, thus being below 
the premenopausal range or at the lower values thereof. No individual value was higher 
than baseline. At the end of follow-up (T3), serum P1NP levels were 44.0±13.8 ng/mL, a 
value close to baseline (p=0.61). The individual values ranged from 25 to 73 ng/mL 
without, therefore, any of them exceeding premenopausal normal values. At this point 
(T3), serum P1NP values were at baseline levels in 4 patients, and above them in 4 
others. 
5.2. Serum CTX levels 
Serum CTX levels (Figure 3) were 0.601±0.223 ng/mL at baseline (T0), and 0.040±0.020 
ng/mL at T1 (p=0.002), accounting for a 93% decrease. At T2, CTX levels were 
0.145±0.115 ng/mL (p=0.004 vs. T1), which still represents a 76% decrease compared to 
baseline levels (p=0.002). The individual values were between 0.033-0.470 ng/mL, and 
none, therefore, exceeded normal premenopausal levels. Finally, at the end of the 
follow-up period (T3), serum CTX levels were 0.242±0.145 ng/mL (p=0.004 vs. baseline). 
Although this means an increase with respect to T2 determination, it still represents a 
60% decrease compared to baseline levels. Again, no individual values were above 
premenopausal normal levels, and none exceeded the baseline values either (although 
in three cases they returned to baseline levels). Therefore, a "rebound phenomenon" of 
CTXs has not been observed in patients who, after discontinuation of denosumab, 
receive a zoledronate injection. 
5.3. BMD 
Regarding BMD, their values at the three locations at times T0, T1 and T3 along with the 
percentage of change at times T1 and T3 vs time T0, are given in Table 2.  
Table 2. BMD at times T0, T1 and T3. BMD changes (in percentage) at times T1 and T3 
compared to T0. 
 
BMD: bone mineral density; T0: baseline (before starting denosumab treatment); T1: 
time of transition from denosumab to zoledronate; T2: 6 months after zoledronate 
injection (there are no data in this column since BMD was not measured at this time); 
T3: end of the follow-up period. : difference in BMD; p: level of significance. 
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BMD was not assessed at T2, because only 6 months had elapsed since T1. Figure 3 
provides a visual image of those changes. As it can be seen, denosumab treatment was 
followed by a marked increase in BMD at the lumbar spine, femoral neck and total hip. 
At the end of the follow-up, the increase in lumbar BMD still represents a significant 9% 
increase over the baseline value. At the hip, however, mean BMD values (either at the 
femoral neck or the total hip) were not significantly different from baseline, but 
nevertheless they were not lower than them.  
Figure 3.  
A. P1NP and CTX after denosumab discontinuation followed by a 5 mg injection of 
zoledronate.  
B. BMD at lumbar spine, femoral neck and total hip after denosumab discontinuation 
followed by a 5 mg injection of zoledronate. 
 
T0: before denosumab administration (baseline); T1: after denosumab administration 
and before the injection of zoledronate; T2: 6 months (approximately) after zoledronate 
injection; T3: at the end of the follow-up (20 months on average) 
All individual values at lumbar spine (Figure 4) rose above the baseline, with the 
exception of a single case, whose value remained at baseline levels. At the end of the 
follow-up (T3), spine BMD values were still above the baseline in 8 patients and had 
returned to baseline in 5. At femoral neck, all individual BMD values at T1 were above 
baseline, with the exception of three cases that remained at baseline level. At the end 
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of follow-up, values were above baseline in 7 patients, at baseline in 5 and below 
baseline in 1. Finally, at the total hip, all individual values were at T1 above baseline 
values, except for a patient who remained at baseline levels. At the end of the follow-
up (T3), BMD values were above baseline in 8 patients and below in 5. 
Figure 4. Individual BMD changes after denosumab discontinuation. 
 
T0: before denosumab administration (baseline); T1: after denosumab administration 
and before the injection of zoledronate; T3: at the end of the follow-up (20 months on 
average). Dotted lines represent the limits of the least significant change. 
5.4. Clinical fractures 
No patient sustained clinical fractures. Since no spine X-rays were performed at the end 




Currently, one of the most important problems when treating osteoporosis, is how to 
deal with patients who discontinue denosumab. It has been reported that denosumab 
discontinuation is followed by an increase in BTM well above baseline (the so called 
“turnover rebound”), along with a loss of BMD and an increase in the risk of fractures, 
particularly of multiple vertebral fractures. We do not yet know the best approach to 
prevent this complication. The administration of a potent antiresorptive agent (mainly 
a bisphosphonate) has been advised by some experts (25) in order to prevent the bone 
turnover rebound and its consequences. However, the number of studies carried out to 
assess the precise effect of antiresorptives on the rebound phenomenon have been 
scarce. We need further studies addressing the issue of whether bisphosphonate 
administration, in particular intravenous zoledronate (the most potent 
bisphosphonate), counteracts the increase in BTM, and to what extent it does.  
In our case series we have found out that two years after zoledronate administration, 
given upon discontinuation of denosumab, CTX levels had increased in relation to the 
values observed at the end of denosumab treatment, but they still remained 60% below 
baseline levels. What is more, no individual value exceeded the baseline. Therefore, not 
only did we not observe any rebound effect, but, in addition, the CTX levels were still 
below those before starting treatment. P1NP levels had also increased in relation to the 
values observed at the end of denosumab treatment. This increase is greater than that 
of CTX, so that they do not remain below baseline level, although they stayed close to 
it. In any case, their mean value did not surpass this baseline. Therefore, again, we can 
state that there was not a generalized rebound phenomenon.  
Nevertheless, the individual values of four patients were above their own baseline 
levels. This apparent discrepancy in these four patients between the pattern of CTX an 
P1NP changes (although perhaps only due to analytic variability) could raise the question 
of whether the higher levels of the P1NP must prevail to decide that there is indeed an 
increase in bone turnover. The replacement of bone tissue, bone turnover, begins with 
the phenomenon of bone resorption. Without bone resorption there is no remodeling, 
and therefore, in mechanistic terms, a resorption marker (CTX) should be a more reliable 
index of bone turnover than a formation marker. In fact, studies on the effect of 
antiresorptive drugs on bone turnover markers (30) report early and large change in 
bone-resorption markers (CTX) compared with bone-formation markers (PINP), 




We are positive that our findings provide compelling evidence that zoledronate 
administration after denosumab discontinuation prevents the phenomenon of rebound. 
In this respect, it is worth emphasising that this phenomenon (a strong increase in bone 
turnover) should not be confused with the degree of elevation of BTM that follows the 
shift of denosumab to zoledronate, which is due to the fact that the former develops on 
osteoclasts a more potent inhibitory effect than the one developed by the latter. 
Consistent with BTM results, BMD decreases, but it remains higher than its values at 
baseline by 9% at the lumbar spine at the end of the follow-up period. As for individual 
values, five returned to baseline levels, but none fell below this. It seems, therefore, 
appropriate to conclude that a zoledronate injection adequately maintains BMD values 
at the lumbar spine for two years. Regarding hip BMD, the mean values at the femoral 
neck and total hip at the end of the follow-up were similar to baseline values. And as for 
their individual values, at the femoral neck only one patient showed a BMD value lower 
than baseline. It is important to bear in mind that this patient had not responded 
previously to denosumab, since after treatment with this drug her femoral neck BMD 
was the same as before. With respect to total hip, the individual values of five of the 
thirteen patients fell below the baseline. This different pattern of BMD changes at the 
hip compared to the lumbar spine is a finding of interest, because the main type of 
fracture that has been reported as increased following denosumab discontinuation is 
vertebral fracture, and not hip fracture. Consequently, the area of the skeleton where 
the risk of fracture after discontinuation of denosumab is greatest is precisely the one 
most protected by zoledronate. Such a greater preventive effect on the lumbar spine 
may take place because the bone turnover is greater in the trabecular bone. 
Finally, none of our patients have sustained clinical fractures over the two-year follow-
up. It must be taken into account that fractures resulting from denosumab 
discontinuation are considered to occur between 9 and 16 months after the last 
injection of the drug. Therefore, the absence of fractures in the two years following 
withdrawal of denosumab along with a subsequent injection of zoledronate, is 
consistent with the idea that zoledronate is effective in preventing the increase in the 
risk of fractures caused by the rebound phenomenon.  
The issue of fractures development after zoledronate administration following 
denosumab discontinuation needs much further research, since very little data have 
been published on this subject. Anastasilakis et al. (26) have published a series of 27 
patients of which only one had vertebral fractures after two years of follow-up. One of 
these fractures was new and the other consisted in the worsening of a preexisting 
vertebral deformity. On the other hand, none of the 6 patients reported by Reid et al. 
(31) nor any of the 22 reported by Lehmann et al. (32) sustained vertebral fractures, 
after a similar two-year follow-up. More recently, Everts-Graber et al (27) have reported 
the development of three vertebral fractures (all single) and four non-nonvertebral 
fractures on 120 patients. One of the vertebral fractures occurred more than two years 
after denosumab discontinuation and the subsequent zoledronate injection. No 
vertebral fractures were neither identified in the retrospective case series conducted by 
Kadaru et al. (33) based on 12 patients. Moreover, 5 of them received a second 
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zoledronate infusion and in this subgroup BMD levels seemed to suffer a general 
stabilization. 
Considering also our case series, this means a total of 199 patients, of whom only 4 have 
had vertebral fractures. That would account for about 0,5% multiple vertebral fractures 
and 1,5% single vertebral fractures. As we still do not know the precise incidence of 
vertebral fractures in patients discontinuing denosumab without further protection with 
an antiresorptive drug, we cannot yet conclude whether or not these figures mean a 
reduction in that incidence. Data from some studies (34) suggest that vertebral fracture 
incidence when denosumab is discontinued without providing protection with other 
antiresorptive drug is larger (about 5-10%). This remains an open question 
notwithstanding. 
Our study has some limitations. It is an observational study, and it was conducted on a 
small number of patients. However, it provides detailed information on the BTM 
changes in patients who discontinue denosumab switching to a zoledronate infusion. 
This is a matter of paramount importance, since it provides the pathophysiological basis 
to establish whether zoledronate prevents or not the rebound phenomenon. In 
addition, we are also providing detailed evidence on BMD changes, having verified that, 
although BMD decreases consistently the slight increase in BTM, such a decrease does 
not imply a return to baseline, in line with the absence of the rebound effect on BTM. 
In conclusion, in patients whose denosumab treatment is discontinued, an infusion of 
zoledronate at the time when a new denosumab injection should be given slows the 
recovery of bone turnover, this way avoiding the rebound phenomenon. Consistent with 
this, bone mass is maintained for two years above baseline in most patients, particularly 
at the lumbar spine. This should reduce the incidence of fractures and, in fact, in our 
series no patient presented any fracture. Further studies are needed to know whether 
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